ReviewKorean circulation journal2025
Pulsta Valve, Unique Self-Expandable Transcatheter Pulmonary Valve.
Review in Korean circulation journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Large sized valve of a self-expandable nature has been suggested as the next generation transcatheter pulmonary valve to implant for various type of native right ventricular outflow tract (RVOT) lesions. Tissue engineered Pulsta valve including decellularization, alpha-galactosidase treatment provide longer valve durability and knitted woven nitinol wire stent provide low risk of stent fracture at the dynamic RVOT. Compact tubular design of Pulsta valve also offer easy valve loading to delivery system and good trackability to valve landing area. From the worldwide experience over 750 cases by February 2025, adaptability of Pulsta valve for various RVOT has proven. Pulsta valve has been implanted for various type of main pulmonary artery (PA) including pyramidal, reverse pyramidal shape and for branch PA stenosis including stent in the branch PA. In case of extremely large native RVOT anatomy, Pulsta valve can be implanted in both branch PA respectively. For the stenotic RVOT or failed bioprosthetic valve, Pulsta valve can also be implanted with or without pre-stenting. Recapturability using delivery system itself if less than one third of valve were flared outside of sheath and capability of whole delivery system retrieval using hooking system are another merit for safe procedure. Though the experience of Pulsta valve for various RVOT diseases is newly accumulated in many centers every day, we still have to learn more about Pulsta valve applicability for various RVOT diseases and long-term outcomes after Pulsta valve implantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.